Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

The American Medical Association and more than two dozen other health organizations joined in an amicus brief encouraging the ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...